Allergic Rhinitis News and Research

RSS

Teva announces additional data from QNASL Phase III program on seasonal allergic rhinitis

Teva Pharmaceutical Industries Ltd. announced today that additional data from the Phase III clinical program for QNASL- (beclomethasone dipropionate) Nasal Aerosol will be presented at the 2012 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Anaheim, CA on November 8-13, 2012.

7 Nov 2012

Allergic rhinitis common in otitis media patients

Allergic rhinitis is a common comorbidity in children with otitis media with effusion, suggest study findings.

2 Nov 2012

Mylan, Shionogi and CIMA Labs to resolve generic Orapred ODT patent litigation

Mylan Inc. today announced that it has entered into a settlement agreement with Shionogi Inc. and CIMA Labs Inc. that will resolve patent litigation related to Prednisolone Sodium Phosphate Orally Disintegrating Tablets (ODT), 10 mg, 15 mg and 30 mg.

10 Oct 2012

Sublingual immunotherapy highly effective for chronic allergy and asthma sufferers

Could it be that those with allergic rhinitis (hay fever) and childhood nasal allergies can finally get a break from their allergies and their allergy shots? Chicago's leading allergy, asthma, and immunology expert, Dr. Brian Rotskoff, who treats a large number of Chicago pediatric allergy patients, is happy to say, "Yes!"

5 Oct 2012

Hebrew University researcher develops anti-inflammatory and anti-allergic family of drugs

A synthetic, anti-inflammatory and anti-allergic family of drugs to combat a variety of illnesses while avoiding detrimental side effects has been developed by a Hebrew University of Jerusalem researcher.

7 Sep 2012

Meritage commences OBS Phase 2 clinical trial for eosinophilic esophagitis

Meritage Pharma, Inc. announced that it has initiated a Phase 2 clinical trial to evaluate oral budesonide suspension (OBS) for the treatment of adolescents and young adults with eosinophilic esophagitis (EoE), an allergic inflammatory condition of the esophagus. EoE is a chronic disease characterized by symptoms related to esophageal dysfunction and eosinophil-predominant inflammation.

13 Aug 2012

Mylan receives final FDA approval for Montelukast Sodium Tablets ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Montelukast Sodium Tablets, 10 mg, the generic version of Merck's Singulair Tablets.

7 Aug 2012

Qualitest confirms launch of generic Singulair Tablets for asthma and allergic rhinitis

Qualitest Pharmaceuticals today confirmed that it has launched a generic version of Singulair (montelukast sodium) Tablets and Chewable Tablets, following the expiration of the last patent that provides Merck U.S. market exclusivity. Qualitest will begin shipping the product immediately. Montelukast Sodium Tablets are labeled for use in treating symptoms of asthma and allergic rhinitis.

6 Aug 2012

First generic versions of Singulair receive FDA approval for treatment of asthma, allergies

The U.S. Food and Drug Administration today approved the first generic versions of Singulair (montelukast sodium) for use in adults and children to control asthma symptoms and to help relieve symptoms of indoor and outdoor allergies.

6 Aug 2012

Sunovion launches ZETONNA Nasal Aerosol for allergic rhinitis

Sunovion Pharmaceuticals Inc. today announced the nationwide availability of ZETONNA (ciclesonide) Nasal Aerosol, 74 mcg once-daily, for the treatment of allergic rhinitis (AR), also known as hay fever or nasal allergies. ZETONNA is a corticosteroid indicated for the treatment of symptoms associated with seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) in adults and adolescents 12 years of age and older.

30 Jul 2012

Food allergies more prevalent among urban children

Children living in urban centers have a much higher prevalence of food allergies than those living in rural areas, according to a new study, which is the first to map children's food allergies by geographical location in the United States. In particular, kids in big cities are more than twice as likely to have peanut and shellfish allergies compared to rural communities.

8 Jun 2012

$6.4 million awarded to investigate mechanisms of allergy tolerance generated by Circassia’s ToleroMune Treatment

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that the United States’ National Institutes of Health (NIH) has awarded a $6.4 million grant to Professor Mark Larché of McMaster University, Canada, to study mechanisms of tolerance developed by patients treated with Circassia’s Toleromune® allergy therapy.

7 Jun 2012

Childhood obesity risk may be increased by caesarean section delivery

Caesarean section delivery may double the risk of subsequent childhood obesity, finds research published online in the Archives of Disease in Childhood.

24 May 2012

Mood disorders not linked to nasal obstruction

While mood disorders like depression or anxiety tend to negatively affect treatment for allergies and chronic rhinosinusitis, the same cannot be said for patients with nasal obstructions such as deviated septum, according to researchers at Henry Ford Hospital.

20 Apr 2012

ACAAI to conduct 16th annual Nationwide Asthma Screening Program

The unseasonably warm weather is making this spring season difficult for millions of Americans who suffer from asthma and allergies. To help adults and children who have symptoms find out if they are at risk, allergists will conduct the 16th annual Nationwide Asthma Screening Program, expanding the program this year to include screening for nasal allergies.

16 Apr 2012

Meda opens China affiliate based in Beijing

Meda has established an affiliate in Hong Kong. At the end of last year, Meda opened its China affiliate based in Beijing. Meda will begin by commercializing two of its well-established products in Hong Kong; Elidel for the treatment of atopic dermatitis (eczema) and azelastine for the treatment of allergic rhinitis.

3 Apr 2012

FDA approves Teva's QNASL nasal aerosol corticosteroid

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has approved QNASL Nasal Aerosol, a new, "dry" nasal aerosol corticosteroid that treats seasonal nasal and year-round nasal allergy symptoms in adults and adolescents 12 years of age and older.

26 Mar 2012

Enrollment complete in HAL Allergy PURETHAL Mites Phase II trial for allergic rhinitis/rhinoconjunctivitis

HAL Allergy B.V. today announced that it has successfully completed patient enrollment in its Phase II dose range finding study. This multi-centre, randomized, double-blind, placebo-controlled study in 250 patients with persistent allergic rhinitis / rhinoconjunctivitis will characterize the dose-response relationship of PURETHAL Mites in order to support the optimal dose in terms of clinical efficacy and safety.

21 Mar 2012

Meda's Astepro receives registration approval in Europe

Astepro has received registration approval in Europe via the decentralized procedure. Astepro is a new nasal spray for the treatment of allergic rhinitis.

21 Mar 2012

AAFA releases new 'Spring Allergy Capital' rankings

Today is the vernal equinox – otherwise known as the official end of winter and the start of spring. But even if you didn't look at your calendar today, chances are your nose already figured it out. That's because more than 40 million Americans have nasal allergies.

20 Mar 2012